Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer
Andreas Schröck MD
Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Andreas Schröck and Friederike Göke contributed equally to this work.
Search for more papers by this authorFriederike Göke MD
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Andreas Schröck and Friederike Göke contributed equally to this work.
Search for more papers by this authorPatrick Wagner MD
Winchester Medical Center, Winchester, Virginia
Search for more papers by this authorMaike Bode
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorAlina Franzen
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorSebastian Huss MD
Institute of Pathology, University of Cologne, Cologne, Germany
Search for more papers by this authorAbbas Agaimy MD
Institute of Pathology, University of Erlangen, Erlangen, Germany
Search for more papers by this authorStephan Ihrler MD
Laboratory for Dermatohistology and Oral Pathology, Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany
Search for more papers by this authorRobert Kirsten
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorGlen Kristiansen MD
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorFriedrich Bootz MD
Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany
Search for more papers by this authorClaudia Lengerke MD
Medical Center II, University of Tuebingen, Tuebingen, Germany
Search for more papers by this authorCorresponding Author
Sven Perner MD, PhD
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Corresponding author: S. Perner, University Hospital of Bonn, Institute of Pathology, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: [email protected]Search for more papers by this authorAndreas Schröck MD
Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Andreas Schröck and Friederike Göke contributed equally to this work.
Search for more papers by this authorFriederike Göke MD
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Andreas Schröck and Friederike Göke contributed equally to this work.
Search for more papers by this authorPatrick Wagner MD
Winchester Medical Center, Winchester, Virginia
Search for more papers by this authorMaike Bode
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorAlina Franzen
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorSebastian Huss MD
Institute of Pathology, University of Cologne, Cologne, Germany
Search for more papers by this authorAbbas Agaimy MD
Institute of Pathology, University of Erlangen, Erlangen, Germany
Search for more papers by this authorStephan Ihrler MD
Laboratory for Dermatohistology and Oral Pathology, Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany
Search for more papers by this authorRobert Kirsten
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorGlen Kristiansen MD
Institute of Pathology, University of Bonn, Bonn, Germany
Search for more papers by this authorFriedrich Bootz MD
Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany
Search for more papers by this authorClaudia Lengerke MD
Medical Center II, University of Tuebingen, Tuebingen, Germany
Search for more papers by this authorCorresponding Author
Sven Perner MD, PhD
Department of Prostate Cancer Research, University of Bonn, Bonn, Germany
Institute of Pathology, University of Bonn, Bonn, Germany
Corresponding author: S. Perner, University Hospital of Bonn, Institute of Pathology, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: [email protected]Search for more papers by this authorAbstract
Background
Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer.
Methods
One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker.
Results
FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16.
Conclusion
FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1253–1257, 2014
REFERENCES
- 1 Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899–905.
- 2 Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359: 722–734.
- 3 Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004; 6: 433–438.
- 4 Bearz A, Berretta M, Lleshi A, Tirelli U. Target therapies in lung cancer. J Biomed Biotechnol 2011; 2011: 921231.
- 5 Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529–541.
- 6 Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005; 65: 5561–5570.
- 7 Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199–213.
- 8 Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165–197.
- 9 Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
- 10 Khademi B, Moradi A, Hoseini S, Mohammadianpanah M. Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. Oral Maxillofac Surg 2009; 13: 191–199.
- 11 Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085–2094.
- 12 Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009; 217: 65–72.
- 13 Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 447–455.
- 14 Göke F, Franzen A, Menon R, et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2012; 142: 1020–1026.
- 15 Schildhaus HU, Heukamp LC, Merkelbach–Bruse S, et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012; 25: 1473–1480.
- 16 Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
- 17 Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
- 18 Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007; 43: 60–66.
- 19 Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 2009; 115: 2701–2709.
- 20 D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944–1956.
- 21 Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709–720.
- 22 Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772–1783.
- 23 Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612–619.
- 24 Syrjänen KJ. HPV infections in benign and malignant sinonasal lesions. J Clin Pathol 2003; 56: 174–181.
- 25 Hoffmann M, Klose N, Gottschlich S, et al. Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett 2006; 239: 64–70.
- 26 El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol 2005; 29: 1367–1372.
- 27 Isayeva T, Li Y, Maswahu D, Brandwein–Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 2012; 6 Suppl 1: S104–S120.
Citing Literature
